Cargando…

Lorlatinib-Induced Pulmonary Embolism in a Patient With an ALK-Positive NSCLC

Detalles Bibliográficos
Autores principales:	Toyozawa, Ryo, Haratake, Naoki, Toyokawa, Gouji, Matsubara, Taichi, Takamori, Shinkichi, Miura, Naoko, Yamaguchi, Masafumi, Takenoyama, Mitsuhiro, Seto, Takashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474371/ https://www.ncbi.nlm.nih.gov/pubmed/34589920 http://dx.doi.org/10.1016/j.jtocrr.2020.100005

Ejemplares similares

Atezolizumab-Induced Aseptic Meningitis in Patients with NSCLC
por: Toyozawa, Ryo, et al.
Publicado: (2020)

Short progression‐free survival of ALK inhibitors sensitive to secondary mutations in ALK‐positive NSCLC patients
por: Haratake, Naoki, et al.
Publicado: (2019)

Brain cavernous hemangioma mimicking radiation‐induced necrosis in a patient with non‐small cell lung cancer
por: Takamori, Shinkichi, et al.
Publicado: (2020)

The impact of immune-inflammation-nutritional parameters on the prognosis of non-small cell lung cancer patients treated with atezolizumab
por: Matsubara, Taichi, et al.
Publicado: (2020)

Histological conversion from adenocarcinoma to small cell carcinoma of the lung after treatment with an immune checkpoint inhibitor: a case report
por: Miura, Naoko, et al.
Publicado: (2020)

Prospective observational study of nutritional/immunologic indices as predictive biomarkers for the response to anti-PD-1 drugs in non-small cell lung cancer (ICI-PREDICT study)
por: Takamori, Shinkichi, et al.
Publicado: (2021)

Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue
por: Takamori, Shinkichi, et al.
Publicado: (2021)

Cohesion between pulmonary artery and bronchus after immune checkpoint inhibitor therapy in a lung cancer patient
por: Takamori, Shinkichi, et al.
Publicado: (2020)

Anti–PD-1 Monotherapy for Advanced NSCLC Patients with Older Age or Those with Poor Performance Status
por: Matsubara, Taichi, et al.
Publicado: (2021)

Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date
por: Akamine, Takaki, et al.
Publicado: (2018)

Uncommon features of surgically resected ALK-positive cavitary lung adenocarcinoma: a case report
por: Takamori, Shinkichi, et al.
Publicado: (2017)

Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
por: Toyokawa, Gouji, et al.
Publicado: (2015)

Combination Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients with NSCLC Receiving Carboplatin-Based Chemotherapy
por: Shimokawa, Mototsugu, et al.
Publicado: (2022)

Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation
por: Takamori, Shinkichi, et al.
Publicado: (2021)

Successful treatment of locally advanced lung cancer using late concurrent chemoradiation therapy administered after immune checkpoint inhibitor plus platinum chemotherapy
por: Matsubara, Taichi, et al.
Publicado: (2021)

Rapidly Destructive Coxarthrosis as a Potential Side Effect of Crizotinib in a Patient with ROS1-Positive Lung Adenocarcinoma
por: Takamori, Shinkichi, et al.
Publicado: (2020)

Recurrence of thymic neuroendocrine carcinoma 24 years after total excision: A case report
por: TOYOKAWA, GOUJI, et al.
Publicado: (2013)

Metabolic characteristics of programmed cell death‐ligand 1‐expressing lung cancer on (18)F‐fluorodeoxyglucose positron emission tomography/computed tomography
por: Takada, Kazuki, et al.
Publicado: (2017)

Sarcoid‐like reaction of the extrathoracic lymph node in a patient with lung adenocarcinoma treated with pembrolizumab
por: Takamori, Shinkichi, et al.
Publicado: (2021)

Update on Lorlatinib: Role in Reducing the Risk of Disease Progression in ALK-Positive NSCLC
por: Yun, Karen M, et al.
Publicado: (2022)

Case report: Success of tepotinib therapy in overcoming resistance to osimertinib in a patient with EGFR-mutant lung adenocarcinoma with a potential acquired MET exon 14 skipping mutation
por: Takamori, Shinkichi, et al.
Publicado: (2022)

The significant influence of having children on the postoperative prognosis of patients with nonsmall cell lung cancer: A propensity score‐matched analysis
por: Takamori, Shinkichi, et al.
Publicado: (2018)

Conservative treatment for residual lung congestion after left upper trisegmentectomy: a case report
por: Nagano, Taichi, et al.
Publicado: (2023)

Lorlatinib Versus Pemetrexed-Based Chemotherapy in Patients With ALK-rearranged NSCLC Previously Treated With Alectinib
por: Takeyasu, Yuki, et al.
Publicado: (2022)

First-Line Lorlatinib Versus Crizotinib in ALK-Positive NSCLC: Japanese Subgroup Analysis of CROWN
por: Hayashi, Hidetoshi, et al.
Publicado: (2023)

Clinical significance of preoperative inflammatory markers in non-small cell lung cancer patients: A multicenter retrospective study
por: Takada, Kazuki, et al.
Publicado: (2020)

A typical carcinoid tumor of the lung presenting with pure persistent ground-glass opacity on high-resolution computed tomography: a case report
por: Yamaguchi, Masafumi, et al.
Publicado: (2017)

A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With ALK-Positive NSCLC in Japan
por: Goto, Yasushi, et al.
Publicado: (2023)

Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis
por: Hochmair, Maximilian J., et al.
Publicado: (2020)

Podcast on Lorlatinib as a First-Line Treatment Option for Patients with ALK-Positive Metastatic NSCLC with Brain Metastasis
por: Liu, Geoffrey, et al.
Publicado: (2023)

Prognostic value of postoperative decrease in serum albumin on surgically resected early-stage non-small cell lung carcinoma: A multicenter retrospective study
por: Kinoshita, Fumihiko, et al.
Publicado: (2021)

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
por: Mizuta, Hayato, et al.
Publicado: (2021)

Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience
por: Rupp, Martin, et al.
Publicado: (2023)

Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced ALK- or ROS1-Rearranged NSCLC: A Brief Report
por: Thummalapalli, Rohit, et al.
Publicado: (2023)

Dynamic monitoring of circulating tumor DNA to analyze genetic characteristics and resistance profile of lorlatinib in ALK positive previously treated NSCLC
por: Ma, Xiya, et al.
Publicado: (2023)

Novel ALK Fusion, PPFIBP1-ALK, in Pancreatic Ductal Adenocarcinoma Responsive to Alectinib and Lorlatinib
por: Gower, Arjan, et al.
Publicado: (2020)

Brain Penetration of the ROS1/ALK Inhibitor Lorlatinib Confirmed by PET
por: Collier, T. Lee, et al.
Publicado: (2017)

Safety and efficacy of lorlatinib against ALK-driven refractory or relapsed neuroblastoma
por: Suk, Yujin, et al.
Publicado: (2023)

Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in ALK-Rearranged NSCLC: A Report of Two Cases
por: Zhu, Viola W, et al.
Publicado: (2020)

Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLC
por: Zhou, Qing, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_seb86sf7ujb3bav0365if5gktb